�Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced that the company has completed enrollment in the second gear of deuce planned phase 3 clinical trials evaluating the base hit and efficaciousness of Prulifloxacin for the treatment of infectious looseness in travelers. The Company previously reported positive top-line data from the number 1 Phase 3 trial which showed that Prulifloxacin met the primary endpoint of Time to Last Unformed Stool (TLUS), a measure of the time to resolution of diarrhea, compared to placebo with a p-value of
Travelers' diarrhea is infectious diarrhea caused by bacteria, viruses or parasites and is contracted by the ingestion of contaminated intellectual nourishment or piddle. This contagion is characterized by looseness along with other related symptoms including nausea, emesis, abdominal pain or cramping, and faecal urgency.
"We are very excited to have completed enrollment in the second trial," aforesaid Michael N. Chang, Ph.D., CEO and President of Optimer. "We look forwards to complemental the analysis of the data from this trial and we expect top-line results in the fourth quarter."
This multi-center, double blind, randomized and placebo-controlled clinical trial compares the base hit and efficaciousness of Prulifloxacin versus placebo in adult travelers suffering from keen bacterial intestinal flu. Clinical trial sites included locations in India, Guatemala, and Mexico. The primary endpoint is TLUS and secondary endpoints include clinical cure based on relief of symptoms and microbiological eradication rates.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products for the intervention of unplayful infections. Optimer has deuce late-stage anti-infective product candidates. OPT-80 is being developed for the treatment of Clostridium difficile infection, the most common hospital-acquired diarrhoea. Prulifloxacin is an antibiotic drug being developed for the treatment of travelers' diarrhoea, a shape of infective diarrhea. Additional information privy be found at hTTP://www.optimerpharma.com.
Forward-looking Statements
Statements included in this press release that are non a description of historical facts ar forward-looking statements, including without limitation all statements related to to Prulifloxacin and the timing of clinical trials and regulatory filings and anticipated results thereof. Words such as "believes," "anticipates," "plans," "expects," "intend," "testament," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of modern statements should not be regarded as a representation by Optimer that whatever of its plans will be achieved. Actual results may differ materially from those put forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product research and development programs, the timing and condition of its preclinical and clinical development of potency drugs and other risks detailed in Optimer's filings with the Securities and Exchange Commission.
Optimer Pharmaceuticals
More info
Wednesday 10 September 2008
Subscribe to:
Posts (Atom)